GALT vs GYRE
GALT: Clinical-stage biopharmaceutical company developing galectin-3 inhibitors derived from plant carbohydrates to treat liver fibrosis, cirrhosis, and cancer. GYRE: A China-based biopharmaceutical company generating revenue from approved antifibrotic treatments while advancing late-stage candidates for liver and other organ fibrosis in the U.S. market.
Side-by-side fundamentals
| Metric | GALT | GYRE | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $3.50 | $5.94 | |
| Market cap as of 2026-07-23 | $253M | $667M | |
| P/E as of 2026-07-23 | n/a | 132.62 | |
| Net margin as of 2026-07-23 | n/a | -5.4% | |
| Gross margin as of 2026-07-23 | n/a | +95.1% | |
| Operating margin as of 2026-07-23 | n/a | -0.1% | |
| ROE as of 2026-07-23 | -258.6% | -6.3% | GYRE higher |
| ROA as of 2026-07-23 | -164.7% | -4.0% | GYRE higher |
| Debt / equity as of 2026-07-23 | 11.09 | 0.00 | GYRE lower |
| Revenue growth (YoY) as of 2026-07-23 | n/a | +16.3% | |
| Revenue CAGR (3y) SEC XBRL | n/a | +4.5% | |
| Dividend streak (yrs) SEC XBRL | n/a | 1 | |
| Beta as of 2026-07-23 | 0.36 | 2.36 | |
| 1-year return as of 2026-07-22 close | +22.4% | -17.8% | GALT higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.